Publications by authors named "K Shiratori"
We present two cases of () respiratory infection. The first case involves a 62-year-old female with abnormal chest shadows, a history of bronchial asthma, and colorectal cancer. Endobronchial ultrasound with a guide sheath (EBUS-GS) revealed granulomatous changes, and was cultured.
View Article and Find Full Text PDFBackground: We aimed to investigate risk factors predicting oxygen demand in COVID-19 patients.
Methods: Patients admitted to Shizuoka General Hospital with COVID-19 from August 2020 to August 2021 were included. First, we divided patients into groups with and without oxygen demand.
Article Synopsis
- Convalescent plasma therapy involves using plasma from recovered COVID-19 patients to treat those with severe cases of the disease.
- A study with 59 participants investigated the safety and efficacy of this therapy, focusing on patients needing ventilation or those who died within two weeks of treatment.
- Preliminary findings suggest that convalescent plasma therapy may be a viable treatment option for COVID-19, and the study aims to support its future use in severe cases.
Article Synopsis
- The study aimed to analyze changes in participant characteristics over time to improve convalescent plasma donation methods for COVID-19 patients.
- Data from April 2020 to November 2021 showed a decrease in sample eligibility, initially below 20% after a year, with a shift toward enrolling more participants beyond 120 days post-infection.
- The research concluded that monitoring eligibility rates and factors like vaccination and infection rates is crucial for effective plasma donation recruitment as pandemics evolve.
Article Synopsis
- A study was conducted to evaluate the effectiveness of convalescent plasma therapy for COVID-19 in high-risk patients who showed symptoms within five days.
- The trial involved 25 patients, with no significant difference in viral load changes between those receiving convalescent plasma and those receiving standard care over the first five days.
- The results suggest that early convalescent plasma treatment does not reduce SARS-CoV-2 viral load compared to standard care alone within that timeframe.